Antiviral Drug Remdesivir Approved as COVID-19 Treatment by FDA
AllSides Summary
Featured Coverage of this Story
From the Center
FDA Approves Remdesivir for Hospitalized COVID-19 Patients After Drug Was Used to Treat Trump
The Food and Drug Administration (FDA) on Thursday approved remdesivir for the treatment of hospitalized COVID-19 patients.
The antiviral treatment, which is made by Gilead Sciences and sold as Veklury, was used to treat President Donald Trump after he contracted the virus earlier this month.
Remdesivir previously received emergency use authorization from the FDA in May for patients with severe cases of COVID-19. The agency later expanded its emergency use authorization in August to include patients who were hospitalized as a result of their COVID-19 infections.
From the Right
FDA approves antiviral drug remdesivir as coronavirus treatment
The Food and Drug Administration granted approval of remdesivir, an antiviral drug from Gilead Sciences and a treatment for COVID-19.
The drug, sold under the name Veklury, will be used for hospitalized COVID-19 patients, Gilead said. It is the first coronavirus disease treatment to receive FDA approval.
“The approval of Veklury marks an important milestone in efforts to help address the pandemic by offering an effective treatment that helps patients recover faster and, in turn, helps preserve scarce healthcare resources,” said Dr. Barry Zingman, a professor at the Albert Einstein...
From the Left
FDA approves remdesivir as treatment for COVID-19 patients in hospital
The Food and Drug Administration (FDA) on Thursday approved the antiviral drug remdesivir as a treatment for patients with COVID-19 who require hospitalization.
Given through an IV, remdesivir works to stop replication of SARS-CoV-2, the virus that causes COVID-19, according to the drug's manufacturer, California-based Gilead Sciences, Inc. Previously authorized by the FDA for emergency use to treat COVID-19, the drug is now the first and only approved COVID-19 treatment in the United States, Gilead said in a release.
“Since the beginning of the COVID-19 pandemic, Gilead has worked relentlessly...
AllSides Picks
June 1st, 2023
May 31st, 2023
May 26th, 2023
More News about Coronavirus from the Left, Center and Right
From the Left
From the Center
From the Right
